By Ridgeline Therapeutics
Proof-of-concept study suggests novel drug has potential to help aging adults become fitter, faster, stronger, and more active
A new report by visiongain calculates that the global melanoma drugs market will reach $89bn in 2018 with revenues showing growth to 2028.
Visiongain has launched a new pharma report Telemedicine Devices Market 2018-2028: Forecasts and Analysis by Device Type (Telemonitors, Peripheral Devices).
By SciTech Development LLC
SciTech's Oncology Drug Granted Orphan Status (GROSSE PONTE FARMS, MI) February 1, 2018 - SciTech Development is pleased to announce that the U.S.
LONDON, UK. 31st January 2018: Visiongain has launched a new pharma report Drug Delivery Technologies Market Forecast 2018-2028: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies;...
Visiongain has launched a new pharma report Orphan Drugs Market Report 2018-2028: Forecasts and Analysis By Therapeutic Class (Oncology, Alimentary Tract & Metabolism, Hormonal Disorders & Haematology, Neuroscience, Respiratory, Cardiovascular,...
By Protzek Gesellschaft für biomedizinische
Protzek, the German leading provider of drug of abuse testing systems, will participate at Medica 2017 trade fair, between the 13th-17th of November, in Dusseldorf.
By Harry Perkins Institute of Medical Research
A new cancer treatment with the dual ability to normalise tumour blood vessels and boost the body's immune system, has been developed by researchers from the Harry Perkins Institute of Medical Research and The University of Western Australia.
By Smartox Biotechonology
Boston, MA - The worldwide expert in animal venom research Smartox Biotechnology based in France opens its first office in the USA to sustain its American development.
LONDON, UK June 2017: Visiongain's new report Global Ophthalmic Drugs Market Forecast 2017-2027: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs indicates that the global ophthalmic drugs market will see..